menu
    • menu
    [{"orgOrder":0,"company":"National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"National Comprehensive Cancer Network \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncology Research Program \/ Taiho Oncology"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Taiho Oncology"}]

    Find Clinical Drug Pipeline Developments & Deals for Futibatinib

    Menu

    Futibatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Boundless Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Boundless Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBI-355,Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Taiho Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTG...

                            Details : Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene ampli...

                            Brand Name : BBI-355

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : BBI-355,Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Taiho Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Commission Grants Conditional Marketing Authorization for Taiho's LYTGOBI® Tablets for the Treatment...

                            Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...

                            Brand Name : Lytgobi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 04, 2023

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CHMP Issues Positive Opinion for Futibatinib for The Treatment of Adults with Cholangiocarcinoma

                            Details : TAS-120 (futibatinib) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarci...

                            Brand Name : TAS-120

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Onco360

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Onco360

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lytgobi® (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated...

                            Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR. It has demonstrated anti-tumor activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.

                            Brand Name : Lytgobi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Oncology Announces Publication in The New England Journal of Medicine of Pivotal Data for Futibatinib in...

                            Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...

                            Brand Name : Lytgobi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2023

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Oncology To Present Phase 2 Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at Virtual ...

                            Details : Key presentations include: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Acquired resistance to ATP-competitive and irreversible FGFR inhibitor...

                            Brand Name : TAS-120

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 02, 2021

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Oncology to Present Futibatinib (TAS-120) Data in Advanced Intrahepatic Cholangiocarcinoma at ESMO Virtu...

                            Details : Abstracts will highlight subgroup analyses of a phase 2 study evaluating efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (i cca) harboring fgfr2 fusions/other rearrangements.

                            Brand Name : TAS-120

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NCCN Oncology Research Program

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            NCCN Oncology Research Program

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Taiho Oncology

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NCCN Oncology Research Program to Get Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression Tog...

                            Details : In a phase 1 dose-escalation trial, futibatinib demonstrated tolerability, pharmacodynamic activity, and preliminary antitumor activity in heavily pretreated patients with advanced solid tumors.

                            Brand Name : TAS-120

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 23, 2020

                            Lead Product(s) : Futibatinib,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Taiho Oncology

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib,Fluorouracil,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Oncology to Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

                            Details : Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 04, 2020

                            Lead Product(s) : Futibatinib,Fluorouracil,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Taiho Oncology

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Oncology Announces Presentation of Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at 2...

                            Details : The interim analysis demonstrated that treatment with the covalently-binding FGFR inhibitor futibatinib may lead to meaningful clinical benefit in patients with refractory iCCA with FGFR2 gene fusions or other rearrangements.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2020

                            Lead Product(s) : Futibatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth